Market Research Logo

Diabetes and Diabetic Complications: Major World Markets


Attention: There is an updated edition available for this report.

The global market for diabetes products, particularly new therapeutics and monitoring products, is a large and growing one. This growth is fueled by three factors --- (1) a rapidly increasing patient population; (2) a back-log of unmet needs, particularly with regard to therapeutics; and (3) advances in biomedical technology that are making possible new products to serve these unmet needs. In this report from Kalorama, the technological and market dynamics of the expanding diabetes markets are analyzed and discussed to give the reader the information necessary to compete in this dynamic field.

Diabetes and its Major Long-Term Complications in Key World Markets assesses the diabetes markets in the seven major world healthcare markets - the United States, France, Germany, Italy, Japan, Spain and the United Kingdom. It discusses the epidemiology of the disease and current attitudes and methods addressing the treatment of both Type 1 and Type 2 diabetes as well as the major long-term complications of diabetes, including hypertension, dyslipidemia, renal complications and neuropathies. Also covered are some of the emerging approaches to the prevention of diabetes and its complications.

The report discusses in detail the newest scientific and technological breakthroughs affecting these markets including new methods of insulin delivery, non-invasive glucose monitoring and new class of antidiabetic drugs. It presents information on the latest products in the field and the emerging product pipeline, as well as detailed analyses of key competitors in the marketplace.


Scope And Methodology

This report focuses on the market applications of current and advanced technology to the development of monitoring and therapeutic products used in the treatment of diabetes (Type 1 and Type 2) and its major complications. It considers the options that they present, the progress that is being made in these fields, and the reception these new products are likely to experience in the marketplace. The major market effects of new diabetes monitoring products and advanced therapeutics are expected to begin to be seen in the relatively short term, that is, within two to three years. The technology trends selected in conjunction with the growing interest in diabetes, diabetic complications and their treatment present the most informative picture of advances in therapeutics for diabetes and diabetic complications, and the markets that result.

This report covers both current therapeutics and current blood glucose monitoring products, in a broad sense. It does not go into the detail of the dynamics of these various products in the marketplace, either branded (proprietary) or generic in the case of drugs. The ability to do so is limited by several factors, and is especially limited where drugs for the treatment of diabetes complications are concerned. For example, antihypertensives and vasodilators used in the treatment of diabetic complications also have broad use in non-diabetic patients. In some cases, they may also have multiple on- and off-label applications for which it is not possible to discriminate among in the marketplace. Moreover, there is mixture of branded and generic products used in the treatment of diabetes and its complications.

This report does discuss, however, the impacts that advanced technologies and applications will have on existing therapeutics markets in the whole. In general, it is the current products and technologies used in the marketplace, leaving significant unmet need, that have placed today’s market in a position that is vulnerable to new technologies and products.

Market analysis for this report considers the diabetes (Type 1 and Type 2) therapeutics and home monitoring markets, as well as the markets for drugs treating the major complications of diabetes in the seven major world healthcare markets:

  • United States
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • United Kingdom

This report does not consider the “downstream” effects of these complications and the needs for certain types of therapeutic equipment and drugs. For example, diabetic foot is a downstream event of peripheral vascular disease resulting from long-term diabetes. While this report discusses the treatment and prevention of peripheral vascular disease, it does not follow on to products used in the treatment of diabetic foot or any of the other sequellae of diabetic peripheral vascular complications. Some mention is made of the need for therapeutic products in this and other areas, but they are not covered in depth. In terms of diabetes home monitoring, the emphasis is on glucose monitoring because this is the major opportunity market in diabetes monitoring. There are other testing areas: ketones and microalbumin. These are not strong market opportunities, however, and represent small markets that are already well served. As a result, they are mentioned but not analyzed in detail.

The focus of the report is on pharmaceutical-based technologies and products with the potential to become first-line monitoring and therapeutic modalities specifically for Type 1 and Type 2 diabetes and their major direct, long-term complications. The analysis presented in this report is based on data from a combination of company, government, industry, institutional, and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including diabetologists, endocrinologists, internists, pathologists, research scientists, business development managers and marketing managers.

Chapter 1: Executive Summary

    Background
    Scope and Methodology
    Size and Growth of Market
    Market Trends
    The Nature of the Industry
    The New Technologies

Chapter 2: Introduction

    Background
    Pathology
    • Type 1 Diabetes
    • Type 2 Diabetes
    • Gestational Diabetes

    Long-Term Complications
    • Hypertension
    • Dyslipidemia
    • Cardiovascular Disease
    • Vascular Complications
    • Diabetic Retinopathy
    • Renal Complications
    • Neuropathies
    • Diabetic Foot

    Epidemiology
    • United States
    • France
    • Germany
    • Italy
    • Japan
    • Spain
    • United Kingdom

Chapter 3: Diabetes Monitoring

    Background
    Glucose Monitoring
    • Glucose
    • Hemoglobin A1c

    Microalbumin

Chapter 4: Current Therapeutic Approaches

    Background
    Therapeutic Practices
    • United States
    • France
    • Germany
    • Italy
    • Japan
    • Spain
    • United Kingdom

    Current Therapeutics for Diabetes
    • Insulins
    • Oral Hypoglycemics

    Current Therapeutics for Diabetic Complications
    • Antihypertensive Therapy
    • Dyslipidemia Therapy
    • Atherosclerosis Therapy
    • Peripheral Vascular Disease Therapy

Chapter 5: Diabetes Monitoring and Therapeutics Markets

    Market Status and Segmentation
    Market Trends
    • United States
    • France
    • Germany
    • Italy
    • Japan
    • Spain
    • United Kingdom

Chapter 6: Forward-Looking Technologies

    Recent Research
    • Prevention
    • Insulin
    • Hypoglycemic Agents

    Insulin Pumps
    Inhaled Insulin
    Oral Insulin
    Gene Therapy
    Transplantation

Chapter 7: Company Profiles

    Abbott Laboratories
    Abgenix, Inc.
    Alkermes
    Amylin Pharmaceuticals
    AstraZeneca
    Aventis Pharma US Division of Aventis
    The Bayer Group (USA) Subsidiary of Bayer AG
    BresaGen Limited
    Bristol-Myers Squibb
    Calyx Therapeutics Inc.
    Cygnus, Inc.
    Diabetogen Biosciences, Inc.
    GlaxoSmithKline
    Lexicon Genetics Inc.
    Eli Lilly & Co.
    Metabolex, Inc.
    MitoKor
    Neurocrine Biosciences
    Novo Nordisk
    O.S.I. Pharmaceuticals
    Pfizer Inc.
    Takeda Pharmaceuticals
    Telik, Inc.
    Transition Therapeutics, Inc.

Chapter 8: Conclusions and Strategic Implications

    Public Health Recognition
    The Pre-eminence of Insulin
    Movement Away from Injection
    Drug Discovery and Innovation
    Insulin and Type 2
    Unmet Need in the Type 2 Market
    Expansion of Type 2 vs Type 1 Markets
    Number of Competitors
    Fate of Finger-Stick Testing
    Timing of New Product Introductions
    Future of Diabetic Complications

Appendix A: Glossary

Appendix B: Company Directory

List of Exhibits
Table 1-1: Market for Insulin in the Seven Major World Healthcare Markets, 1999-2007
Table 1-2: Market for Oral Hypoglycemics in the Seven Major World Healthcare Markets, 1999-2007
Table 1-3: Market for Drugs to Treat Diabetic Complications in the Major World Healthcare Markets, 1999-2007
Table 2-1: Characteristics of Type 1 and Type 2 Diabetes Mellitus
Table 2-2: Common Symptoms and Conditions of Diabetes Mellitus
Table 2-3: Prevalence Rates for Diagnosed Type 1 and Type 2 Diabetes Mellitus in the Seven Major World Healthcare Markets, 1999-2007
Table 2-4: Diagnosed Diabetes Population for the Seven Major World Healthcare Markets, 1999-2007
Table 3-1: Key Glucose Monitoring Products on the Market
Table 3-2: Key Ketone Monitoring Products on the Market
Table 4-1: Estimated Number of Preventable Diabetes Cases and Complications in the United States
Table 4-2: Insulin Products for the Treatment of Type 1 Diabetes
Table 4-3: Drugs in Development for the Treatment of Type 1 Diabetes
Table 4-4: Oral Hypoglycemics for the Treatment of Type 2 Diabetes
Table 4-5: Drugs in Clinical Development for the Treatment of Type 2 Diabetes
Table 4-6: Common ACE Inhibitors on the Market for Diabetic Hypertension
Table 4-7: Common Adrenergic Receptors on the Market for Diabetic Hypertension
Table 4-8: Common Calcium Channel Blockers on the Market for Diabetic Hypertension
Table 4-9: Common Combined Diuretic Products on the Market for Diabetic Hypertension
Table 4-10: Common Angiotensin II Receptor Antagonists on the Market for Diabetic Hypertension
Table 4-11: Commonly Used Anti-Lipemic Agents on the Market for Diabetic Dyslipidemia
Table 4-12: Vaughn Williams Classification of Anti-Arrhythmic Drugs
Table 4-13: Currently Marketed Anti-Arrhythmatic Drugs
Table 4-14: Drugs Used to Combat Diabetic Peripheral Vascular Disease
Table 4-14: Drugs Used to Combat Diabetic Peripheral Vascular Disease
Table 5-2: Estimated Market Sizes for Insulin in the Seven Major World Healthcare Markets, 1999-2007
Table 5-3: Estimated Market Sizes for Oral Hypoglycemics in the Seven Major World Healthcare Markets, 1999-2007
Table 5-4: Estimated Market Sizes for Drugs to Treat Diabetic Complications in the Seven Major World Healthcare Markets, 1999-2007
Table 5-5: Estimated Diabetes-Care Market Size in the United States, 1999-2007
Table 5-6: Estimated Diabetes-Care Market Size in France, 1999-2007
Table 5-7: Estimated Diabetes-Care Market Size in Germany, 1999-2007
Table 5-8: Estimated Diabetes-Care Market Size in Italy, 1999-2007
Table 5-9: Estimated Diabetes-Care Market Size in Japan, 1999-2007
Table 5-10: Estimated Diabetes-Care Market Size in Spain, 1999-2007
Table 5-11: Estimated Diabetes-Care Market Size in the United Kingdom, 1999-2007
Figure 1-1: Diagnosed and Undiagnosed Diabetes Cases in the Major World Healthcare Markets, 1999-2007
Figure 1-2: Trending in the Major Blood Glucose Monitoring Markets, 1999-2007
Figure 2-1: Diagnosed and Undiagnosed Diabetes Cases in the Seven Major World Healthcare Markets, 1999-2007
Figure 2-2: Composition of the Diagnosed Diabetes Patient Population in the Seven Major World Healthcare Markets, 2001 and 2007
Figure 2-3: Geographic Distribution of the Diagnosed Diabetes Patient Population, 2001
Figure 2-4: Geographic Distribution of the Diagnosed , Type 1 Diabetes Patient Population, 2001
Figure 2-5: Geographic Distribution of the Diagnosed Type 2 Diabetes Patient Population: 2001
Figure 2-6: General Population Distribution for the Seven Major World Healthcare Markets, 2001
Figure 2-7: Historic and Forecast Diagnosed Diabetes Cases in the United States, 1999-2007
Figure 2-8: Historic and Forecast Diagnosed Diabetes Cases in France, 1999-2007
Figure 2-9: Historic and Forecast Diagnosed Diabetes Cases in Germany, 1999-2007
Figure 2-10: Historic and Forecast Diagnosed Diabetes in Italy, 1999-2007
Figure 2-11: Historic and Forecast Diagnosed Diabetes in Japan, 1999-2007
Figure 2-12: Historic and Forecast Diagnosed Diabetes in Spain, 1999-2007
Figure 2-13: Historic and Forecast Diagnosed Diabetes in the United Kingdom, 1999-2007
Figure 5-1: Trending in the World’s Major Blood Glucose Monitoring Markets, 1999-2007
Figure 5-2: Distribution of the Blood Glucose Monitoring Markets by Country
Figure 5-3: Market Shares of the Key Participants in the Major World Markets for Glucose Monitoring Products, 2001
Figure 5-4: Trending in the World’s Major Markets for Insulin, 1999-2007
Figure 5-5: Market Distribution in the World’s Major Markets for Insulin, 1999-2007
Figure 5-6: Estimated Insulin Market Shares in the Seven Major World Healthcare Markets, 2001
Figure 5-7: Trending in the World’s Major Markets for Oral Hypoglycemic Drugs, 1999-2007
Figure 5-8: Market Distribution in the World’s Major Markets for Oral Hypoglycemics, 1999-2007
Figure 5-9: Estimated Oral Hypoglycemic Drug Market Shares in the Seven Major World Healthcare Markets, 2001
Figure 5-10: Trending in the Total World’s Major Markets for Drugs to Treat Diabetic Complications by Complication, 1999-2007
Figure 5-11: Composition of the Total World’s Major Markets for Drugs to Treat Diabetic Complications by Complication, 1999-2007
Figure 5-12: Trending in the United States Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-13: Composition of the United States Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-14: Trending in the French Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-15: Composition of the French Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-16: Trending in the German Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-17: Composition of the German Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-18: Trending in the Italian Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-19: Composition of the Italian Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-20: Trending in the Japanese Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-21: Composition of the Japanese Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-22: Trending in the Spanish Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-23: Composition of the Spanish Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-24: Trending in the United Kingdom Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-25: Composition of the United Kingdom Market for Diabetes-Care Products by Product Class, 1999-2007

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report